Standardized diagnosis and treatment guidelines are the “guide light” for cancer diagnosis and treatment. The reporter learned at the press conference of the 2022 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference held recently that, in response to the living conditions, diagnosis and treatment problems of Chinese cancer patients, the Chinese Society of Clinical Oncology has updated or released 17 guidelines for the diagnosis and treatment of different cancer fields this year. , there will be a number of guides available in the second half of the year.
The latest data from the National Cancer Center shows that there are about 4.06 million new cancer cases and 2.41 million deaths nationwide in one year. In recent years, the 5-year survival rate of cancer has improved significantly, but there is still a big gap compared with developed countries.
The Healthy China Action Cancer Prevention and Control Action proposes to formulate and promote the application of common cancer diagnosis and treatment norms and clinical pathways. By 2022 and 2030, the overall cancer 5-year survival rate will be no less than 43.3% and 46.6%, respectively.
To standardize cancer diagnosis and treatment and improve the overall 5-year survival rate of cancer requires authoritative and scientific diagnosis and treatment guidelines. Since the release of the Lung Cancer Guidelines in 2016, the Chinese Society of Clinical Oncology’s diagnosis and treatment guidelines have become an important reference and basis for many oncologists’ daily work. Over the past six years, more than one million copies of the guidelines have been issued.
2022 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference Press Conference Site (Photo provided by the interviewee)
“Based on evidence-based medicine, referring to the opinions of industry experts, adapting to my country’s specific national conditions, taking into account regional differences, fully considering the availability of diagnosis and treatment resources, reflecting the value of tumor treatment and health economic indicators, it is a member of the Chinese Society of Clinical Oncology. The basic principles of guideline formulation.” said Xu Ruihua, chairman of the Chinese Society of Clinical Oncology.
“The guidelines of the Chinese Society of Clinical Oncology have always taken into account regional development differences, the availability of diagnosis and treatment methods and the social value of tumor treatment, and are committed to recommending the best treatment plan for China and similar countries and regions.” China Jiang Zefei, vice president and secretary general of the Society of Clinical Oncology, said.
To improve the level of cancer diagnosis and treatment, it is very important to formulate a plan suitable for Chinese cancer patients. Jiang Zefei introduced that, taking the “2022 Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines” as an example, the new version of the guidelines closely follows the cutting-edge academic progress, incorporates the latest international and domestic progress based on the actual situation in China, and lists drugs according to the latest national medical insurance drug list. The recommendation level is adjusted to ensure the professionalism, rigor, authority and accessibility of the guideline. (Reporter Xu Penghang)
(Source: Xinhua News Agency)
[Source: Xinhua News Agency]